Johnson & Johnson and Actelion are reported to be asking Switzerland's takeover board about the viability of a complicated takeover deal the U.S. healthcare company is discussing with the Swiss biotech firm. Ciara Lee reports.
A deal is edging closer - if newspaper headlines are to be believed anyway. Johnson & Johnson and Actelion have reportedly asked Switzerland's takeover board about the viability of a deal. Johnson & Johnson would acquire Actelion while separating its commercialised portfolio from its research and development assets. The panel's preliminary review is apparently ongoing, one Swiss paper said. The Swiss takeover board, which determines whether a deal meets legal requirements did not immediately comment. The proposed deal structure would allow U.S. healthcare company J&J to acquire Swiss biotech firm Actelion with a cash offer in the region of $260 per share. That's a little more than what it had offered when it walked away from negotiations in December.